Among the patients with APS, the incidence of IgA aCL and IgA anti-β2-GP1 was higher than that in the study by Hu et al. [9]; their findings showed that the patients with PAPS had IgA aCL in 11.76% of cases and IgA anti-β2-GP1 in 10.46%, and these antibodies among the patients with secondary APS were 25.42% and 20.34%, respectively. The gene discussed is CD79A; the disease is autoimmune polyendocrinopathy.